Compare Alphabet Inc Class A (GOOGL) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Eli Lilly And Co — how do they compare? Alphabet Inc Class A trades at $351.6 (market cap $4.24T), while Eli Lilly And Co trades at $1,177.57 (market cap $1.04T). The key difference: Alphabet Inc Class A is far larger — about 4.1× Eli Lilly And Co's market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and Eli Lilly And Co for 93 Days on average.
| GOOGL | LLY | |
|---|---|---|
Market Cap | $4.24T | $1.04T |
Volume | 23,392,850 | 3,064,878 |
Sector | Media | Health |
52-Week High | $402.62 | $1.28K |
52-Week Low | $236.59 | $799.57 |
Typical Hold Time | 85 Days | 93 Days |
Enterprise Value | $4.13T | $1.09T |
Dividend Yield | 0.25% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $351.66, up 0.33% with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Recent earnings beats and a 86.75% analyst buy rating support positive sentiment, while YouTube's subscription price increase and AI partnerships with Anthropic and Intel highlight growth initiatives.
GOOGL presents a compelling investment case with 72 buy ratings and a $431.83 consensus price target offering 23% upside. Strong cash flow generation ($164.7B operating cash flow in 2025) and AI leadership position the stock for continued growth, though antitrust scrutiny and market volatility remain key risks requiring monitoring.
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
